Aggressive B-cell non-Hodgkin lymphomas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology

Abstract

Aggressive B-cell non-Hodgkin lymphomas are a heterogeneous group of diseases and our concepts are evolving as we learn more about their clinical, pathologic, molecular genetic features. Session IV of the 2020 EAHP Workshop covered aggressive, predominantly high-grade B-cell lymphomas, many that were difficult to classify. In this manuscript, we summarize the features of the submitted cases and highlight differential diagnostic difficulties. We specifically review issues related to high-grade B-cell lymphomas (HGBCLs) with MYC and BCL2 and/or BCL6 rearrangements including TdT expression in these cases, HGBCL, not otherwise specified, large B-cell lymphomas with IRF4 rearrangement, high-grade/large B-cell lymphomas with 11q aberration, Burkitt lymphoma, and pleomorphic mantle cell lymphoma. Since the workshop, the 5th edition of the WHO Classification for Haematolymphoid Tumours (WHO-HAEM5) and International Consensus Classification (ICC) 2022 were published. We endeavor to use the updated terminology.

Cytogenetic and pathologic characterization of MYC-rearranged B-cell lymphomas in pediatric and young adult patients

“…Our study design did not allow for specific identification of this phenomenon. While HGBCL-DH- BCL6 lymphomas appear molecularly and prognostically heterogeneous [ 24 , 26 , 30 , 33 – 36 , 38 , 39 ], potential distinct clinico-biologic correlates of “pseudo-double hit” BCL remain poorly studied [ 36 , 40 , 41 ]. Accordingly, further data is needed to assess the clinical relevance of genetic testing to identify BCL6::MYC rearrangements.…”

Anomaly Detection and Artificial Intelligence Identified the Pathogenic Role of Apoptosis and RELB Proto-Oncogene, NF-kB Subunit in Diffuse Large B-Cell Lymphoma

“…The diagnostic criteria of DLBCL are heterogeneous and include several subtypes such as T cell/histiocyte-rich large B cell lymphoma, the primary DLBCL of the mediastinum, intravascular large B cell lymphoma, lymphomatoid granulomatosis, the primary DLBCL of the central nervous system, the primary cutaneous DLBCL leg type, DLBCL associated with chronic inflammation, and Epstein-Barr virus-positive (EBER)-positive DLBCL. In the WHO classification, other categories are included [1,2,5], which have features of overlap between DLBCL and other subtypes (Burkitt lymphoma), such as high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements and high-grade B-cell lymphoma not otherwise specified [18][19][20][21][22][23][24][25][26][27][28][29][30][31][32].…”